GlassScriptPhysician profile
Tara L Murphy
NPI 1801428842
$3,037.37
in general payments reported to CMS, 2019-2025
27 companies · $64.57 in 2025
The $64.57 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $444 · 2022: $764 · 2023: $831 · 2024: $934 · 2025: $64.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,829.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $767.04 | 2021-2024 | |
| Daiichi Sankyo INC. | $193.92 | 2021-2024 | Injectafer |
| Abbvie INC. | $193.69 | 2021-2025 | |
| Exeltis, USA INC. | $188.55 | 2021-2024 | Slynd |
| Agile Therapeutics, INC. | $173.64 | 2021-2024 | Twirla |
| Astellas Pharma US INC | $166.45 | 2022-2025 | Veozah |
| Biogen, INC. | $143.72 | 2022-2024 | Zurzuvae |
| Mylan Pharmaceuticals INC. | $131.25 | 2021-2022 | |
| Pfizer INC. | $111.38 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.45 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $100.71 | 2023-2024 | Myfembree, Gemtesa |
| Merck Sharp & Dohme LLC | $98.47 | 2022-2024 | Gardasil 9, Gardasil |
| Coopersurgical, INC. | $90.48 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Evofem Biosciences, INC. | $78.58 | 2021-2024 | |
| Amgen INC. | $63.16 | 2021-2024 | Evenity, Prolia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $62.82 | 2021-2022 | |
| Organon LLC | $54.99 | 2021-2024 | |
| Avion Pharmaceuticals | $49.92 | 2021 | |
| Hologic Sales and Service, LLC | $47.90 | 2024 | Aptima |
| Scynexis, INC. | $39.88 | 2022 | |
| Shield Therapeutics INC | $38.12 | 2023 | Accrufer |
| Medtronic, INC. | $37.91 | 2024-2025 | Truclear, Venaseal |
| Novo Nordisk INC | $30.95 | 2023-2024 | Wegovy |
| Gilead Sciences, INC. | $21.97 | 2023 | |
| Exact Sciences Corporation | $20.33 | 2024 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $14.76 | 2022 | |
| Cepheid | $14.33 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.